Лечение артериальной гипертензии: есть ли место для b-адреноблокаторов?
Аннотация
Об авторе
Л. О. МинушкинаРоссия
Список литературы
1. Thorin E, Thorin-Trescases N. Vascular endothelial ageing, heartbeat after heartbeat. Cardiovasc Res 2009; 84 (1): 24–32.
2. Bangalore S, Messerli F.H., Kostis J.B., Pepine C.J. Cardiovascular protection using b - blockers: a critical review of the evidence. J Am Coll Cardiol 2007; 50: 563–72.
3. Williams B, Lacy P.S., Thom S.M. et al. Differential impact of blood pressure - lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113 (9): 1213–25.
4. Magid D.J., Shetterly S.M., Margolis K.L. et al. Comparative effectiveness of angiotensin - converting enzyme inhibitors vs b - blockers as second - line therapy for hypertension circ. Cardiovasc Qual Outcomes 2010; 3: 453–8.
5. Oğuz A, Uzunlulu M, Yorulmaz E et al. Effect of nebivolol and metoprolol treatments on serum asymmetric dimethy larginine levels in hypertensive patients with type 2 diabetes mellitus. Anadolu Kardiyol Derg 2007; 7 (4): 383–7.
6. Zepeda R.J., Castillo R, Rodrigo R. et al. Effect of carvedilol and nebivolol on oxidative stress - related parameters and endothelial function in patients with essential hypertension. Basic Clin Pharmacol Toxicol 2012; 111 (5): 309–16.
7. Feng M.G., Prieto M.C., Navar L.G. Nebivolol - induced vasodilation of renal afferent arterioles involves b3-adrenergic receptor and nitric oxide synthase activation. Am J Physiol Renal Physiol 2012; 303 (5): 775–82.
8. Lewin A, Lasseter K.C., Dong F, Whalen J.C. Nebivolol withdrawal results in blood pressure returning toward pretreatment levels, but without rebound symptoms: phase IV randomized trial. J Am Soc Hypertens 2012; 6 (3): 228–36.
9. Acelajado M.C., Pisoni R, Dudenbostel T. et al. Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients. J Am Soc Hypertens 2012; 6 (1): 66–72.
10. Lindamood C, Ortiz S, Shaw A. et al. Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug - drug interaction studies. J Clin Pharmacol 2011; 51 (4): 575–85.
11. Lewin A, Punzi H, Luo X. et al. Nebivolol monotherapy for patients with systolic stage II hypertension: results of a randomized, placebo - controlled trial. Clin Ther 2013. http://pii: S0149-2918(12)00730-8. doi: 10.1016/j.clinthera.2012.12.015
12. Weiss R.J., Saunders E, Greathouse M. Efficacy and tolerability of nebivolol in stage I–II hypertension: a pooled analysis of data from three randomized, placebo - controlled monotherapy trials. Clin Ther 2011; 33 (9): 1150–61.
13. Greathouse M. Nebivolol efficacy and safety in patients with stage I–II hypertension. Clin Cardiol 2010; 33 (4): e20–7.
14. Germino F.W., Lin Y, Pejović V, Bowen L. Efficacy and tolerability of nebivolol: does age matter? A retrospective analysis of three randomized, placebo - controlled trials in stage I–II hypertension. Ther Adv Cardiovasc Dis 2012; 6 (5): 185–99.
15. Cağlar N, Dincer I. Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end - point (PROBE) trial. Eur Rev Med Pharmacol Sci 2011; 15 (12): 1359–68.
16. Vinereanu D, Gherghinescu C, Ciobanu A.O. et al. Reversal of subclinical left ventricular dysfunction by antihypertensive treatment: a prospective trial of nebivolol against metoprolol. J Hypertens 2011; 29 (4): 809–17.
17. Soanker R, Naidu M.U., Raju S.B. et al. Effect of b1-blocker, nebivolol, on central aortic pressure and arterial stiffness in patients with essential hypertension. Indian J Pharmacol 2012; 44 (3): 407–11.
18. Mahmud A, Feely J. B-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens 2008; 21 (6): 663–7.
19. Kampus P, Serg M, Kals J et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension 2011; 57 (6): 1122–8.
20. Bortel L.M. Efficacy, tolerability and safety of nebivolol in patients with hypertension and diabetes: a post - marketing surveillance study. Eur Rev Med Pharmacol Sci 2010; 14 (9): 749–58.
21. Badar V.A., Hiware S.K., Shrivastava M.P. et al. Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension. Indian J Pharmacol 2011; 43 (4): 437–40.
22. Merchant N, Rahman S.T., Ferdinand K.C. et al. Effects of nebivolol in obese African Americans with hypertension (NOAAH): markers of inflammation and obesity in response to exercise - induced stress. J Hum Hypertens 2011; 25 (3): 196–202.
23. Schmidt A.C., Graf C, Brixius K, Scholze J. Blood pressure - lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study. Clin Drug Investig 2007; 27 (12): 841–9.
24. Martiniuc C, Branishte T. The use of b - blocker Nebivolol in patients with chronic obstructive pulmonary disease in association with arterial hypertension. Rev Med Chir Soc Med Nat Iasi 2012; 116 (1): 218–21.
25. Espinola-Klein C, Weisser G, Jagodzinski A et al. b-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension 2011;58 (2): 148–54.
26. Diehm C, Pittrow D, Lawall H. Effect of nebivolol vs hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication. J Hypertens 2011; 29 (7): 1448–56.
Рецензия
Для цитирования:
Минушкина Л.О. Лечение артериальной гипертензии: есть ли место для b-адреноблокаторов? Системные гипертензии. 2013;(1):48-51.
For citation:
Minushkina L.O. Hypertension treatment: Is there a place for b-adrenoblockers? Systemic Hypertension. 2013;(1):48-51.
Послать статью по эл. почте 